STERIS Announces Financial Results for Fiscal 2027 Second Quarter
Key Highlights
- ➤Q2 revenue $1.6B, up 9%; constant-currency organic growth reached 8%
- ➤Adjusted EPS $2.94, up from $2.47 year over year
- ➤Fiscal 2027 adjusted EPS outlook raised to $11.35-$11.55 from $11.10-$11.30
- ➤Life Sciences revenue surged 18% to $170.6M; segment outlook raised to 9%-10% growth
- ➤New restructuring plan expects $45M charges and approximately $9M annualized savings
Expert Statements
Dan Carestio, President and CEO of STERIS
“We are pleased with our second quarter performance.”
Dan Carestio, President and CEO of STERIS
“Life Sciences delivered particularly strong performance in the quarter, giving us confidence to raise our expectations for the segment for the full year.”
Dan Carestio, President and CEO of STERIS
“Our updated outlook reflects stable underlying performance, plus the benefit of tariff refunds received year-to-date.”
Dan Carestio, President and CEO of STERIS
“Fiscal 2027 is shaping up to be another record year for STERIS, supported by solid underlying demand and excellent execution from our commercial teams.”
* Fiscal 2027 second quarter revenue increased 9%; constant currency organic revenue growth was 8% * Fiscal 2027 second quarter as reported diluted EPS increased to $2.19; adjusted EPS per diluted share increased to $2.94 * Outlook updated to reflect solid underlying performance and the benefit of tariff refunds DUBLIN, IRELAND, Nov. 04, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2027 second quarter ended September 30, 2026. Total revenue for the second quarter of fiscal 2027 increased 9% to $1.6 billion compared with $1.5 billion in the second quarter of fiscal 2026. Constant currency organic revenue growth was 8% in the second quarter.
“We are pleased with our second quarter performance,” said Dan Carestio, President and CEO of STERIS. “Life Sciences delivered particularly strong performance in the quarter, giving us confidence to raise our expectations for the segment for the full year. Our updated outlook reflects stable underlying performance, plus the benefit of tariff refunds received year-to-date. Fiscal 2027 is shaping up to be another record year for STERIS, supported by solid underlying demand and excellent execution from our commercial teams.”
Get started
Create a free account to read the full story.